There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments.
UK-based Small Pharma has launched on the Toronto's TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-Dimethyltryptamine (DMT) to tre
After two FDA rejections for non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA), Intercept Pharma has agreed to be taken over by Italian drugmaker Alfasig
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho